Genmab to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 09h52 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; January 2, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 42nd Annual J.P. Morgan...
Genmab to Hold 2023 R&D Update and ASH Data Review Meeting
12 déc. 2023 07h00 HE
|
Genmab A/S
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 12, 2023 – Genmab A/S (Nasdaq: GMAB) will hold its 2023 R&D Update and...
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
09 déc. 2023 12h00 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
05 déc. 2023 17h26 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; December 5, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 7,054 shares as a consequence of the exercise of employee warrants. The...
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
27 nov. 2023 07h00 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 27, 2023 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for the treatment of relapsed or...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
21 nov. 2023 16h45 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
21 nov. 2023 16h42 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,541 restricted stock units to members of the Board of...
Major Shareholder Announcement
09 nov. 2023 09h14 HE
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 9, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
Genmab to Present at Jefferies London Healthcare Conference
09 nov. 2023 05h00 HE
|
Genmab A/S
Media Release COPENHAGEN, Denmark; November 9, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano...
Major Shareholder Announcement
08 nov. 2023 11h09 HE
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; November 8, 2023 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...